Aktis Oncology (NASDAQ:AKTS) Trading Down 8.2% – Should You Sell?

Aktis Oncology (NASDAQ:AKTS) shares traded down 8.2% during mid-day trading on Friday . The company traded as low as $28.85 and last traded at $28.60. 457,848 shares traded hands during trading, an increase of 45% from the average session volume of 315,832 shares. The stock had previously closed at $31.15.

Analyst Ratings Changes

Several research firms recently commented on AKTS. William Blair initiated coverage on shares of Aktis Oncology in a research report on Wednesday, April 29th. They issued an “outperform” rating for the company. Raymond James Financial started coverage on shares of Aktis Oncology in a research report on Monday, June 15th. They set a “strong-buy” rating and a $40.00 price objective on the stock. HC Wainwright lifted their price objective on shares of Aktis Oncology from $33.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, June 2nd. Finally, Weiss Ratings raised shares of Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Aktis Oncology has an average rating of “Moderate Buy” and an average price target of $34.00.

Aktis Oncology Stock Down 5.5%

The business has a 50 day moving average price of $20.89.

Aktis Oncology (NASDAQ:AKTS) last issued its quarterly earnings results on Monday, March 30th. The technology company reported ($18.17) EPS for the quarter. The company had revenue of $1.87 million for the quarter. As a group, research analysts anticipate that Aktis Oncology will post -1.62 EPS for the current year.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.